BRIEF-Cytokinetics And Royalty Pharma Announce Expanded Strategic Funding Collaboration Of Up To $575 Mln

Reuters05-23

May 22 (Reuters) - Cytokinetics Inc :

* CYTOKINETICS AND ROYALTY PHARMA ANNOUNCE EXPANDED STRATEGIC FUNDING COLLABORATION TOTALING UP TO $575 MILLION TO SUPPORT COMMERCIAL LAUNCH OF AFICAMTEN AND TO ADVANCE RESEARCH AND DEVELOPMENT PIPELINE

* CYTOKINETICS INC - ROYALTY PHARMA WILL NOW RECEIVE 4.5% UP TO $5.0 BILLION OF ANNUAL NET SALES OF AFICAMTEN AND 1% ABOVE $5.0 BILLION OF ANNUAL NET SALES

* CYTOKINETICS INC - CYTOKINETICS WILL RECEIVE $100 MILLION IN UPFRONT CAPITAL TO FUND A CONFIRMATORY PHASE 3 CLINICAL TRIAL OF OMECAMTIV MECARBIL

Source text for Eikon: Further company coverage:

((reuters.briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2437243565?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-23 04:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2437243565","market":"us","top_or_hot":-1,"title":"BRIEF-Cytokinetics And Royalty Pharma Announce Expanded Strategic Funding Collaboration Of Up To $575 Mln","media":"Reuters","content":"<html><body><p>May 22 (Reuters) - <a href=\"https://laohu8.com/S/CYTK\">Cytokinetics</a> Inc   :</p><p>   * CYTOKINETICS AND ROYALTY PHARMA ANNOUNCE EXPANDED STRATEGIC FUNDING COLLABORATION TOTALING UP TO $575 MILLION TO SUPPORT COMMERCIAL LAUNCH OF AFICAMTEN AND TO ADVANCE RESEARCH AND DEVELOPMENT PIPELINE</p><p>   * CYTOKINETICS INC -  ROYALTY PHARMA WILL NOW RECEIVE 4.5% UP TO $5.0 BILLION OF ANNUAL NET SALES OF AFICAMTEN AND 1% ABOVE $5.0 BILLION OF ANNUAL NET SALES</p><p>   * CYTOKINETICS INC - CYTOKINETICS WILL RECEIVE $100 MILLION IN UPFRONT CAPITAL TO FUND A CONFIRMATORY PHASE 3 CLINICAL TRIAL OF OMECAMTIV MECARBIL</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cytokinetics And Royalty Pharma Announce Expanded Strategic Funding Collaboration Of Up To $575 Mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cytokinetics And Royalty Pharma Announce Expanded Strategic Funding Collaboration Of Up To $575 Mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-23 04:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>May 22 (Reuters) - Cytokinetics Inc   :   * CYTOKINETICS AND ROYALTY PHARMA ANNOUNCE EXPANDED STRATEGIC FUNDING COLLABORATION TOTALING UP TO $575 MILLION TO SUPPORT COMMERCIAL LAUNCH OF AFICAMTEN AND ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2437243565","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437243565","pubTimestamp":1716408192,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"May 22  - Cytokinetics Inc   :   * CYTOKINETICS AND ROYALTY PHARMA ANNOUNCE EXPANDED STRATEGIC FUNDING COLLABORATION TOTALING UP TO $575 MILLION TO SUPPORT COMMERCIAL LAUNCH OF AFICAMTEN AND TO ADVANCE RESEARCH AND DEVELOPMENT PIPELINE   * CYTOKINETICS INC -  ROYALTY PHARMA WILL NOW RECEIVE 4.5% UP TO $5.0 BILLION OF ANNUAL NET SALES OF AFICAMTEN AND 1% ABOVE $5.0 BILLION OF ANNUAL NET SALES   * CYTOKINETICS INC - CYTOKINETICS WILL RECEIVE $100 MILLION IN UPFRONT CAPITAL TO FUND A CONFIRMATORY PHASE 3 CLINICAL TRIAL OF OMECAMTIV MECARBILSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4007":"制药","CYTK":"Cytokinetics","RPRX":"Royalty Pharma plc"},"translate_title":"简介-Cytokinetics和Royalty Pharma宣布扩大战略资金合作，高达5.75亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":1,"RPRX":0.9},"content_text":"May 22 (Reuters) - Cytokinetics Inc   :   * CYTOKINETICS AND ROYALTY PHARMA ANNOUNCE EXPANDED STRATEGIC FUNDING COLLABORATION TOTALING UP TO $575 MILLION TO SUPPORT COMMERCIAL LAUNCH OF AFICAMTEN AND TO ADVANCE RESEARCH AND DEVELOPMENT PIPELINE   * CYTOKINETICS INC -  ROYALTY PHARMA WILL NOW RECEIVE 4.5% UP TO $5.0 BILLION OF ANNUAL NET SALES OF AFICAMTEN AND 1% ABOVE $5.0 BILLION OF ANNUAL NET SALES   * CYTOKINETICS INC - CYTOKINETICS WILL RECEIVE $100 MILLION IN UPFRONT CAPITAL TO FUND A CONFIRMATORY PHASE 3 CLINICAL TRIAL OF OMECAMTIV MECARBILSource text for Eikon:    Further company coverage:    ((reuters.briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437243565"}